Mission Statement, Vision, & Core Values of iTeos Therapeutics, Inc. (ITOS)

Are you curious about what drives a biopharmaceutical company focused on revolutionizing cancer treatments? Let's delve into the core of iTeos Therapeutics, Inc. (ITOS), a company dedicated to pioneering the discovery and development of next-generation immuno-oncology therapeutics. But what exactly is their mission, and what values guide their path in this challenging field? With a 178% increase in revenue to $35 million in 2024, do you wonder how their mission and vision fuel such growth, despite a net loss of $134.4 million?

iTeos Therapeutics, Inc. (ITOS) An Overview of

iTeos Therapeutics, Inc. is a biopharmaceutical company focused on the development of innovative cancer immunotherapies. The company is dedicated to translating scientific understanding of new immune-modulatory pathways into effective treatments for cancer patients. Iteos's pipeline includes several clinical-stage programs targeting key mechanisms of immune suppression within the tumor microenvironment.

As of April 2025, iTeos Therapeutics continues to advance its clinical programs, including those evaluating the anti-TIGIT antibody EOS-448 and the adenosine A2A receptor antagonist inupadenant. These therapies are being investigated as monotherapies and in combination with other anti-cancer agents. The company’s research and development efforts are supported by strategic collaborations and financial investments aimed at expanding its portfolio and accelerating the development of novel cancer treatments.

In its latest financial reports, iTeos Therapeutics highlighted significant progress in its clinical trials and research programs. While specific revenue figures may vary depending on the reporting period, the company's financial stability is underpinned by strategic partnerships and investments that support ongoing research and development activities.

iTeos Therapeutics operates in a competitive landscape within the biopharmaceutical industry, focusing on immuno-oncology. The company aims to differentiate itself through innovative approaches to targeting the tumor microenvironment and enhancing anti-cancer immune responses.

To delve deeper into iTeos Therapeutics, Inc.'s financial strengths and strategic positioning, explore: Breaking Down iTeos Therapeutics, Inc. (ITOS) Financial Health: Key Insights for Investors

iTeos Therapeutics, Inc. (ITOS) Mission Statement

iTeos Therapeutics, Inc. (ITOS) is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of patients with cancer by designing and developing next-generation immunotherapies. The company's mission is centered around pioneering the discovery and development of highly differentiated immuno-oncology therapeutics. iTeos leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer.

Founded with the mission to revolutionize cancer treatments, iTeos focuses on understanding the complexities of tumor immunology and developing novel therapies that can help patients fight cancer more effectively.

iTeos' competitive edge lies in combining expertise in drug discovery and translational tumor immunology. They utilize a unique platform to identify rational combinations of immunotherapies and novel targets. The data generated using these systems helps enable the identification and testing of next-generation immuno-oncology therapeutics that will ultimately benefit cancer patients.

iTeos' philosophy on corporate responsibility reflects unity among its stakeholders, which is an essential pillar for building a resilient and responsible business. This commitment extends beyond therapeutic development and is rooted in nurturing a vibrant culture of ownership and community, empowering the company to construct a sustainable business for a brighter future.

The company's innovative pipeline includes programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes.

Driven by a culture of scientific innovation, collaboration, and excellence, iTeos aims to discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.

iTeos Therapeutics is headquartered in Watertown, MA, with a research center in Gosselies, Belgium.

iTeos Therapeutics has a transformative $2.145 billion co-development and co-commercialization agreement with GSK for its anti-TIGIT monoclonal antibody, EOS-448.

Core Values of iTeos Therapeutics, Inc. (ITOS)

iTeos Therapeutics' values form the foundation of the company's identity and define its core principles:

• Data Driven: Driven by scientific curiosity, iTeos follows the data where they lead.
• Ownership: Taking initiative and responsibility, employees are empowered to deliver results that will change lives.
• Courage: iTeos has the courage to stand for bold ideas because improving the lives of people with cancer requires audacity and urgency.
• Stronger Together: Achieving common goals by collaborating and valuing differences.

Commitment to Employees and ESG

iTeos is committed to integrating Environmental, Social, and Governance (ESG) principles into its operations to create sustainable value for society and all stakeholders. Each member of the iTeos family is a vital contributor to achieving the mission of improving the lives of people with cancer.

As of December 31, 2023, iTeos had 157 full-time employees. Women represent 58% of the global workforce and 49% of leadership positions at the Director level or above. The Executive Committee is 33% female.

The company prioritizes several United Nations Sustainable Development Goals (SDGs) where it can make the greatest difference:

• Good health and well-being
• Quality education
• Gender equality
• Decent work and economic growth
• Reduced inequalities
• Sustainable cities and communities
• Responsible consumption and production
• Climate action
• Peace, justice, and strong institutions

The company embraces cultural, ethnicity, racial, gender identity, sexual orientation, cognitive, social, and professional diversity because it recognizes that new cures are made possible by working together.

Read more about iTeos Therapeutics, Inc. (ITOS) Exploring iTeos Therapeutics, Inc. (ITOS) Investor Profile: Who’s Buying and Why?

iTeos Therapeutics, Inc. (ITOS) Vision Statement of

While a specific, stand-alone vision statement for iTeos Therapeutics, Inc. is not explicitly available in the provided search results, insights into the company's aspirations and long-term goals can be gleaned from its mission, values, and strategic objectives. These elements collectively paint a picture of what iTeos envisions for its future and its role in the biopharmaceutical landscape.

Here is what can be gathered about their focus and direction:

• Focus on Immuno-Oncology: iTeos is dedicated to pioneering the discovery and development of innovative cancer immunotherapies for patients.
• Transforming the Lives of Patients: The company aims to improve and extend the lives of cancer patients by developing next-generation immunotherapies.
• Innovative Science: iTeos emphasizes the importance of rigorous scientific research in identifying and developing novel therapeutic candidates.
• Strong Pipeline: A key aspect of iTeos' vision involves advancing a robust pipeline of product candidates targeting various aspects of the tumor microenvironment.

iTeos's pipeline includes:

• EOS-448: An antagonistic anti-TIGIT antibody.
• Inupadenant: An adenosine A2a receptor antagonist.
• EOS-850: A small molecule designed to inhibit the histone deacetylase (HDAC) family.

Commitment to Collaboration: iTeos recognizes the value of strategic collaborations and partnerships in accelerating the development and commercialization of its therapies.

iTeos's financial standing as of the 2024 fiscal year reflects its commitment to these goals. For example, iTeos reported cash, cash equivalents, and marketable securities of $551.9 million as of December 31, 2024. Research and development expenses were $124.7 million for the year ended December 31, 2024.

Advancing Science and Innovation

Central to iTeos's vision is a commitment to cutting-edge science and innovation. This involves:

• Investing in research and development to identify novel targets and therapeutic candidates.
• Utilizing advanced technologies and platforms to accelerate drug discovery and development.
• Fostering a culture of scientific excellence and collaboration.

Building a Sustainable Company

iTeos aims to create a sustainable and impactful biopharmaceutical company by:

• Attracting and retaining top talent in the industry.
• Building a strong financial foundation to support long-term growth.
• Operating with integrity and transparency in all aspects of its business.

In summary, while a formal vision statement may not be publicly available, iTeos Therapeutics's vision can be understood through its dedication to innovative immuno-oncology research, its focus on improving patient outcomes, its strategic collaborations, and its commitment to building a sustainable and impactful company. These elements collectively define the company's aspirations for the future and its role in transforming the treatment of cancer.

To gain further insights into iTeos Therapeutics, Inc., explore iTeos Therapeutics, Inc. (ITOS): History, Ownership, Mission, How It Works & Makes Money.

iTeos Therapeutics, Inc. (ITOS) Core Values of

At iTeos Therapeutics, the mission is to make a meaningful difference in the lives of people with cancer. You can gain more insights into the company's background on: iTeos Therapeutics, Inc. (ITOS): History, Ownership, Mission, How It Works & Makes Money. This commitment is reflected in their core values, which guide their actions and decisions. While specific details of iTeos Therapeutics' core values are not available, one can infer potential core values based on their operations and industry standards. Here are some possible core values:

Innovation: In the biotechnology industry, innovation is crucial for developing new therapies and improving patient outcomes. iTeos Therapeutics likely values innovation as a driver of their research and development efforts.

Patient-Centricity: A focus on patients is fundamental for any company in the healthcare sector. This involves understanding patient needs, prioritizing their well-being, and striving to develop treatments that improve their quality of life.

Integrity: Maintaining the highest ethical standards is essential in the pharmaceutical industry. Integrity ensures that research is conducted responsibly, data is reported accurately, and interactions with healthcare professionals and patients are transparent.

Collaboration: The development of new cancer therapies often requires collaboration between researchers, institutions, and other companies. iTeos Therapeutics likely values collaboration as a means to leverage diverse expertise and accelerate progress.

Scientific Excellence: A commitment to rigorous scientific research and development is vital for creating effective and safe treatments. This includes investing in cutting-edge technologies, attracting top talent, and adhering to the highest standards of scientific rigor.

These core values likely underpin iTeos Therapeutics' operations and strategic decisions, reflecting their dedication to advancing cancer treatment and improving patient outcomes.